**SUPPLEMENTARY FILE 1**

**RESULTS FOR THE COMPLETE CASE ANALYSIS OF THE DUTCH VALIDATION COHORT (N = 92)**

EXTERNAL VALIDATION METHOD SELECTED WAS KEEPING THE ORIGINAL MODEL

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary table 1.** Model performance of the original model (Postoperative model) and the updated models for the Dutch cohort (n = 92) . | | | | |
|  | **Original**  **model** | **Recalibration-in-the-large a** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration interceptc | 0.0907 | 0 | 0 | 0 |
| Calibration slopec | 0.9109 | 0.9109 | 1 | 1 |
| *c*-statistic | 0.689 | 0.689 | 0.689 | 0.782 |
| Brier score | 0.192 | 0.192 | 0.192 | 0.164 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -1.750777 | -1.585199 | -1.504091 | -0.638587 |
| Age at diagnosis | 0.004381937 | 0.004381937 | 0.003991409 | 0.016615385 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.0348905 | 1.0348905 | 0.9426588 | 1.0885347 |
| Stage IIIC | 1.12037349 | 1.12037349 | 0.96927043 | -0.01375294 |
| Stage IV | 1.4854454 | 1.4854454 | 1.3530592 | 0.1098793 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.196292 | 1.196292 | 1.089676 | 10.290969 |
| Endometrioid | 0.02379306 | 0.02379306 | 0.02167257 | 0.55194132 |
| Clear cell | 1.0008111 | 1.0008111 | 0.9116166 | 1.7348003 |
| Adenocarcinoma NOS | -0.06078587 | -0.06078587 | -0.05536850 | -7.08356951 |
| Other | 1.0056858 | 1.0056858 | 0.9160569 | -7.2143737 |
| Presence of ascites |  |  |  |  |
| No | -0.1703497 | -0.1703497 | -0.1551678 | -0.2806274 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment level of CA-125 |  |  |  |  |
|  | 9.990522e-06 | 9.990522e-06 | 9.100145e-06 | -2.167181e-04 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.7290635 | 0.7290635 | 0.6640878 | 1.2663233 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.557798 | -1.557798 | -1.418964 | -2.439584 |
| ≤1 cm | -0.7263164 | -0.7263164 | -0.6615855 | -1.0375788 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the postoperative model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |

Afbeelding met tekst, diagram, lijn, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, diagram, lijn, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, diagram, lijn, Perceel

Automatisch gegenereerde beschrijving

**RESULTS FOR 1ST IMPUTATED DATASET OF THE DUTCH VALIDATION COHORT (N =1212)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary table 2.** Model performance of the original model (Postoperative model) and the updated models for the Dutch cohort (n = 1212). | | | | |
|  | **Original**  **model** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | -0.2817 | 0 | 0 | 0. |
| Calibration slope | 1.0165 | 1.0165 | 1 | 1 |
| *c*-statistic | 0.713 | 0.713 | 0.713 | 0.722 |
| Brier score | 0.158 | 0.158 | 0.158 | 0.157 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -1.750777 | -2.044825 | -2.061297 | -1.612059 |
| Age at diagnosis |  |  |  |  |
|  | 0.004381937 | 0.004381937 | 0.004454073 | 0.005451432 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.0348905 | 1.0348905 | 1.0519270 | 0.3843756 |
| Stage IIIC | 1.120373 | 1.120373 | 1.138817 | 0.824873 |
| Stage IV | 1.485445 | 1.485445 | 1.509899 | 1.047990 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.196292 | 1.196292 | 1.215986 | 1.785058 |
| Endometrioid | 0.02379306 | 0.02379306 | 0.02418474 | 0.46486088 |
| Clear cell | 1.000811 | 1.000811 | 1.017287 | 1.430983 |
| Adenocarcinoma NOS | -0.06078587 | -0.06078587 | -0.06178654 | -0.15168808 |
| Other | 1.005686 | 1.005686 | 1.022242 | 1.407690 |
| Presence of ascites |  |  |  |  |
| No | -0.1703497 | -0.1703497 | -0.1731540 | 0.1547347 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  | 9.990522e-06 | 9.990522e-06 | 1.015499e-05 | 4.309158e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.7290635 | 0.7290635 | 0.7410655 | 0.7179001 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.557798 | -1.557798 | -1.583443 | -1.992822 |
| ≤1 cm | -0.7263164 | -0.7263164 | -0.7382732 | -1.1598715 |
| >1 cm | Reference | Reference | Reference | Reference |
| Abbreviations:  The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the postoperative model. | | | | |

Afbeelding met tekst, lijn, schermopname, diagram

Automatisch gegenereerde beschrijvingAfbeelding met tekst, diagram, lijn, schermopname

Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, schermopname

Automatisch gegenereerde beschrijving

**RESULTS FOR 2ND IMPUTATED DATASET OF THE DUTCH VALIDATION COHORT (N =1212)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary table 3.** Model performance of the original model (Postoperative model) and the updated models for the Dutch cohort (n = 1212) . | | | | |
|  | **Postoperative model** | **Recalibration-in-the-large a** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration interceptc | -0.2858 | 0 | 0 | 0 |
| Calibration slopec | 1.0155 | 1.0155 | 1 | 1 |
| *c*-statistic | 0.713 | 0.713 | 0.713 | 0.730 |
| Brier score | 0.158 | 0.158 | 0.158 | 0.155 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -1.750777 | -2.048098 | -2.063704 | -1.891283 |
| Age at diagnosis |  |  |  |  |
|  | 0.004381937 | 0.004381937 | 0.004449877 | 0.009616763 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.0348905 | 1.0348905 | 1.0509359 | 0.3594379 |
| Stage IIIC | 1.120373 | 1.120373 | 1.1377443 | 0.8058405 |
| Stage IV | 1.485445 | 1.485445 | 1.508476 | 1.010276 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.196292 | 1.196292 | 1.214840 | 1.910658 |
| Endometrioid | 0.02379306 | 0.02379306 | 0.02416196 | 0.60936871 |
| Clear cell | 1.000811 | 1.000811 | 1.016328 | 1.437549 |
| Adenocarcinoma NOS | -0.06078587 | -0.06078587 | -0.06172832 | -0.26838395 |
| Other | 1.005686 | 1.005686 | 1.021278 | 1.310337 |
| Presence of ascites |  |  |  |  |
| No | -0.1703497 | -0.1703497 | -0.17299087 | -0.09855768 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment level of CA-125 |  |  |  |  |
|  | 9.990522e-06 | 9.990522e-06 | 1.014542e-05 | 8.812498e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.7290635 | 0.7290635 | 0.7403672 | 0.6530778 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.557798 | -1.557798 | -1.581951 | -1.846641 |
| ≤1 cm | -0.7263164 | -0.7263164 | -0.7375776 | -1.1008244 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the postoperative model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |
|  | | | | |

**RESULTS FOR 3RD IMPUTATED DATASET OF THE DUTCH VALIDATION COHORT (N =1212)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary table 4.** Model performance of the original model (Postoperative model) and the updated models for the Dutch cohort (n = 1212) . | | | | |
|  | **Original**  **model** | **Recalibration-in-the-large a** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration interceptc | -0.2956 | 0 | 0 | 0 |
| Calibration slopec | 0.9876 | 1.0155 | 1 | 1 |
| *c*-statistic | 0.710 | 0.713 | 0.713 | 0.730 |
| Brier score | 0.159 | 0.159 | 0.159 | 0.158 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -1.750777 | -2.036981 | -2.024733 | -1.643195 |
| Age at diagnosis |  |  |  |  |
|  | 0.004381937 | 0.004381937 | 0.004327760 | 0.005196011 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.0348905 | 1.0348905 | 1.0220954 | 0.3851003 |
| Stage IIIC | 1.120373 | 1.120373 | 1.1065215 | 0.8617294 |
| Stage IV | 1.485445 | 1.485445 | 1.467080 | 1.097073 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.196292 | 1.196292 | 1.181501 | 1.784666 |
| Endometrioid | 0.02379306 | 0.02379306 | 0.02349889 | 0.58607959 |
| Clear cell | 1.000811 | 1.000811 | 0.9884373 | 1.3972126 |
| Adenocarcinoma NOS | -0.06078587 | -0.06078587 | -0.06003433 | -0.17186361 |
| Other | 1.005686 | 1.005686 | 0.9932518 | 1.2648473 |
| Presence of ascites |  |  |  |  |
| No | -0.1703497 | -0.1703497 | -0.1682435 | 0.1896779 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment level of CA-125 |  |  |  |  |
|  | 9.990522e-06 | 9.990522e-06 | 9.867002e-06 | 3.059530e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.7290635 | 0.7290635 | 0.7200496 | 0.6879664 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.557798 | -1.557798 | -1.538538 | -1.946401 |
| ≤1 cm | -0.7263164 | -0.7263164 | -0.7173365 | -1.1478935 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the postoperative model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |
|  | | | | |

**RESULTS FOR THE COMPLETE CASE ANALYSIS OF THE DUTCH VALIDATION COHORT (N = 88)**

EXTERNAL VALIDATION METHOD SELECTED WAS KEEPING THE ORIGINAL MODEL

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3.** Model performance of the original model (*BRCA* model) and the updated models for the Dutch cohort (n = 88). | | | | |
|  | **Original**  **model** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | 0.3255 | 0 | 0 | 0 |
| Calibration slope | 0.7764 | 0.7764 | 1 | 1 |
| *c*-statistic | 0.692 | 0.691 | 0.692 | 0.800 |
| Brier score | 0.198 | 0.197 | 0.198 | 0.167 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -2.0591549 | -1.4720647 | -1.2731253 | -0.6446981 |
| Age at diagnosis |  |  |  |  |
|  | -0.008876547 | -0.008876547 | -0.006891444 | 0.015975385 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.339122 | 1.339122 | 1.039648 | 1.200403 |
| Stage IIIC | 1.5449104 | 1.5449104 | 1.1994150 | 0.3263759 |
| Stage IV | 1.711979 | 1.711979 | 1.329121 | 0.282906 |
| *BRCA* status |  |  |  |  |
| *BRCA-negative* | Reference | Reference | Reference | Reference |
| *BRCA1* mutation | -0.6162172 | -0.6162172 | -0.4784097 | 0.4575990 |
| *BRCA2* mutation | -1.672580 | -1.672580 | -1.298533 | -7.136382 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.572044 | 1.572044 | 1.220481 | 10.890372 |
| Endometrioid | -0.2965935 | -0.2965935 | -0.2302649 | 0.4726973 |
| Clear cell | 0.7662715 | 0.7662715 | 0.5949067 | 1.5491067 |
| Adenocarcinoma NOS | 0.01501892 | 0.01501892 | 0.01166017 | -7.84063979 |
| Other | 0.7582711 | 0.7582711 | 0.5886955 | -8.2410808 |
| Presence of ascites |  |  |  |  |
| No | -0.1338588 | -0.1338588 | -0.1039233 | -0.2094358 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  | 1.828824e-05 | 1.828824e-05 | 1.419836e-05 | -2.050930e-04 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.9895219 | 0.9895219 | 0.7682306 | 0.9809809 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.2402636 | -1.2402636 | -0.9628978 | -2.4177096 |
| ≤1 cm | -0.4503319 | -0.4503319 | -0.3496221 | -1.0012815 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘keeping the original model’ as the preferred method for updating the BRCA model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |

Afbeelding met tekst, diagram, lijn, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, diagram, lijn, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, diagram, lijn, Perceel

Automatisch gegenereerde beschrijving

Afbeelding met tekst, diagram, lijn, Perceel

Automatisch gegenereerde beschrijving


**RESULTS FOR 1ST IMPUTATED DATASET OF THE DUTCH VALIDATION COHORT (N = 793)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3.** Model performance of the original model (*BRCA* model) and the updated models for the Dutch cohort (n = 793). | | | | |
|  | **Original**  **model** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | 0.0541 | 0 | 0 | 0 |
| Calibration slope | 0.8370 | 0.8370 | 1 | 1 |
| *c*-statistic | 0.696 | 0.696 | 0.696 | 0.704 |
| Brier score | 0.172 | 0.172 | 0.172 | 0.168 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -2.059155 | -1.816311 | -1.669405 | -1.517114 |
| Age at diagnosis |  |  |  |  |
|  | -0.0088765472 | -0.0088765472 | -0.0074295372 | -0.0005584114 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.3391216 | 1.3391216 | 1.1208248 | 0.6070045 |
| Stage IIIC | 1.544910 | 1.544910 | 1.293067 | 1.238237 |
| Stage IV | 1.711979 | 1.711979 | 1.432901 | 1.508680 |
| *BRCA* status |  |  |  |  |
| *BRCA-negative* | Reference | Reference | Reference | Reference |
| *BRCA1* mutation | -0.6162172 | -0.6162172 | -0.5157646 | -0.7077404 |
| *BRCA2* mutation | -1.6725800 | -1.6725800 | -1.3999245 | -0.9344422 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.5720443 | 1.5720443 | 1.3157776 | 0.9734949 |
| Endometrioid | -0.2965935 | -0.2965935 | -0.2482443 | 0.5560097 |
| Clear cell | 0.7662715 | 0.7662715 | 0.6413578 | 0.9688911 |
| Adenocarcinoma NOS | 0.01501892 | 0. 01501892 | 0.01257061 | -0.27950114 |
| Other | 0.7582711 | 0.7582711 | 0.6346616 | 1.7301589 |
| Presence of ascites |  |  |  |  |
| No | -0.13385880 | -0.13385880 | -0.11203781 | 0.05479659 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  | 1.828824e-05 | 1.828824e-05 | 1.530698e-05 | 3.291002e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.9895219 | 0.9895219 | 0.8282150 | 0.5704867 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.240264 | -1.240264 | -1.038082 | -1.570526 |
| ≤1 cm | -0.4503319 | -0.4503319 | -0.3769211 | -0.9808051 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the BRCA model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |

Afbeelding met tekst, lijn, diagram, schermopname

Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, schermopname

Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, schermopname, diagram

Automatisch gegenereerde beschrijving

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3.** Model performance of the original model (*BRCA* model) and the updated models for the Dutch cohort (n = 793). | | | | |
|  | **Original**  **model** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | 0.0690 | 0 | 0 | 0 |
| Calibration slope | 0.8468 | 0.8468 | 1 | 1 |
| *c*-statistic | 0.699 | 0.699 | 0.699 | 0.705 |
| Brier score | 0.173 | 0.172 | 0.171 | 0.169 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -2.059155 | -1.812386 | -1.674751 | -1.431614 |
| Age at diagnosis |  |  |  |  |
|  | -0.008876547 | -0.008876547 | -0.007517039 | -0.001336263 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.3391216 | 1.3391216 | 1.1340254 | 0.6296903 |
| Stage IIIC | 1.544910 | 1.544910 | 1.308296 | 1.223832 |
| Stage IV | 1.711979 | 1.711979 | 1.449777 | 1.516212 |
| *BRCA* status |  |  |  |  |
| *BRCA-negative* | Reference | Reference | Reference | Reference |
| *BRCA1* mutation | -0.6162172 | -0.6162172 | -0.5218390 | -0.7470213 |
| *BRCA2* mutation | -1.672580 | -1.672580 | -1.416412 | -1.029570 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.572044 | 1.572044 | 1.331274 | 0.963163 |
| Endometrioid | -0.2965935 | -0.2965935 | -0.2511680 | 0.8237056 |
| Clear cell | 0.7662715 | 0.7662715 | 0.6489114 | 0.8765382 |
| Adenocarcinoma NOS | 0.01501892 | 0.01501892 | 0.01271866 | -0.31125066 |
| Other | 0.7582711 | 0.7582711 | 0.6421364 | 1.6125829 |
| Presence of ascites |  |  |  |  |
| No | -0.1338588 | -0.1338588 | -0.1133573 | -0.2017251 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  | 1.828824e-05 | 1.828824e-05 | 1.548726e-05 | 2.282636e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.9895219 | 0.9895219 | 0.8379694 | 0.6090087 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.240264 | -1.240264 | -1.050308 | -1.477765 |
| ≤1 cm | -0.4503319 | -0.4503319 | -0.3813603 | -0.9205736 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the BRCA model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |

**RESULTS FOR 2ND IMPUTATED DATASET OF THE DUTCH VALIDATION COHORT (N = 793)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

**RESULTS FOR 3RD IMPUTATED DATASET OF THE DUTCH VALIDATION COHORT (N = 793)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3.** Model performance of the original model (*BRCA* model) and the updated models for the Dutch cohort (n = 793). | | | | |
|  | **Original**  **model** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | 0.07727 | 0 | 0 | 0 |
| Calibration slope | 0.85422 | 0.85422 | 1 | 1 |
| *c*-statistic | 0.700 | 0.700 | 0.700 | 0.706 |
| Brier score | 0.172 | 0.171 | 0.171 | 0.168 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -2.059155 | -1.813043 | -1.681708 | -1.710227 |
| Age at diagnosis |  |  |  |  |
|  | -0.008876547 | -0.008876547 | -0.007582543 | 0.001068138 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.3391216 | 1.3391216 | 1.1439073 | 0.7198843 |
| Stage IIIC | 1.544910 | 1.544910 | 1.319697 | 1.312243 |
| Stage IV | 1.711979 | 1.711979 | 1.462410 | 1.604292 |
| *BRCA* status |  |  |  |  |
| *BRCA-negative* | Reference | Reference | Reference | Reference |
| *BRCA1* mutation | -0.6162172 | -0.6162172 | -0.5263863 | -0.8679045 |
| *BRCA2* mutation | -1.672580 | -1.672580 | -1.428755 | -1.011789 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.5720443 | 1.5720443 | 1.3428750 | 0.9775429 |
| Endometrioid | -0.2965935 | -0.2965935 | -0.2533567 | 0.8651783 |
| Clear cell | 0.7662715 | 0.7662715 | 0.6545661 | 1.0745143 |
| Adenocarcinoma NOS | 0.01501892 | 0.01501892 | 0.01282949 | -0.34115749 |
| Other | 0.7582711 | 0.7582711 | 0.6477320 | 1.6226473 |
| Presence of ascites |  |  |  |  |
| No | -0.1338588 | -0.1338588 | -0.1143451 | -0.1808081 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  | 1.828824e-05 | 1.828824e-05 | 1.562222e-05 | 5.108871e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.9895219 | 0.9895219 | 0.8452715 | 0.5357407 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.240264 | -1.240264 | -1.059461 | -1.059461 |
| ≤1 cm | -0.4503319 | -0.4503319 | -0.3846835 | -0.8965033 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the BRCA model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |

**RESULTS FOR THE COMPLETE CASE ANALYSIS OF THE AUSTRALIAN VALIDATION COHORT (N = 981)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary table 1.** Model performance of the original model (Postoperative model) and the updated models for the Australian cohort (N = 981) . | | | | |
|  | **Original**  **model** | **Recalibration-in-the-large a** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration interceptc | 0.2949 | 0 | 0 | 0 |
| Calibration slopec | 0.9196 | 0.9196 | 1 | 1 |
| *c*-statistic | 0.697 | 0.697 | 0.697 | 0.720 |
| Brier score | 0.213 | 0.208 | 0.208 | 0.203 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -1.7507769 | -1.3913957 | -1.3417099 | -0.5621041 |
| Age at diagnosis |  |  |  |  |
|  | 0.004381937 | 0.004381937 | 0.004145709 | -0.001687839 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.0348905 | 1.0348905 | 0.9791001 | -0.3314615 |
| Stage IIIC | 1.1203735 | 1.1203735 | 1.0599747 | 0.5024938 |
| Stage IV | 1.4854454 | 1.4854454 | 1.4053658 | 0.9071132 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.196292 | 1.196292 | 1.131800 | 1.331036 |
| Endometrioid | 0.02379306 | 0.02379306 | 0.02251039 | -0.36759654 |
| Clear cell | 1.0008111 | 1.0008111 | 0.9468579 | 1.5325172 |
| Adenocarcinoma NOS | -0.06078587 | -0.06078587 | -0.05750894 | -0.65013044 |
| Other | 1.0056858 | 1.0056858 | 0.9514698 | 0.7904149 |
| Presence of ascites |  |  |  |  |
| No | -0.1703497 | -0.1703497 | -0.1611662 | -0.288653 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment level of CA-125 |  |  |  |  |
|  | 9.990522e-06 | 9.990522e-06 | 9.451938e-06 | 2.600123e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.7290635 | 0.7290635 | 0.6897601 | 1.1450775 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.557798 | -1.557798 | -1.473818 | -1.331774 |
| ≤1 cm | -0.7263164 | -0.7263164 | -0.6871611 | -0.6235259 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the postoperative model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |

Afbeelding met tekst, diagram, lijn, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, Perceel

Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, Perceel

Automatisch gegenereerde beschrijving

**RESULTS FOR 1ST IMPUTATED DATASET OF THE AUSTRALIAN VALIDATION COHORT (N = 1334)**

EXTERNAL VALIDATION METHOD SELECTED WAS MODEL REVISION

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  | | --- | --- | --- | --- | --- | | **Supplementary table 1.** Model performance of the original model (Postoperative model) and the updated models for the Australian cohort (N = 1334) . | | | | | |  | **Original**  **model** | **Recalibration-in-the-large a** | **Recalibration** | **Model revision** | | ***Model performance*** |  |  |  |  | | Calibration interceptc | 0.2025 | 0 | 0 | 0 | | Calibration slopec | 0.8642 | 0.8642 | 1 | 1 | | *c*-statistic | 0.686 | 0.686 | 0.686 | 0.707 | | Brier score | 0.211 | 0.208 | 0.208 | 0.203 | |  |  |  |  |  | | ***Coefficients*** |  |  |  |  | | Intercept | -1.7507769 | -1.4348220 | -1.3105189 | -0.8785003 | | Age at diagnosis |  |  |  |  | |  | 0.004381937 | 0.004381937 | 0.003786960 | 0.003542047 | | FIGO stage |  |  |  |  | | Stage IIB-IIC | Reference | Reference | Reference | Reference | | Stage IIIA-IIIB | 1.0348905 | 1.0348905 | 0.8943736 | -0.4355153 | | Stage IIIC | 1.1203735 | 1.1203735 | 0.9682498 | 0.3580138 | | Stage IV | 1.4854454 | 1.4854454 | 1.2837524 | 0.8608914 | | Histologic subtype |  |  |  |  | | Serous | Reference | Reference | Reference | Reference | | Mucinous | 1.1962919 | 1.1962919 | 1.0338601 | 0.5506158 | | Endometrioid | 0.02379306 | 0.02379306 | 0.02056245 | -0.32883423 | | Clear cell | 1.0008111 | 1.0008111 | 0.8649215 | 1.4559284 | | Adenocarcinoma NOS | -0.06078587 | -0.06078587 | -0.05253240 | -0.42706715 | | Other | 1.0056858 | 1.0056858 | 0.8691344 | 0.5591493 | | Presence of ascites |  |  |  |  | | No | -0.1703497 | -0.1703497 | -0.1472197 | -0.3577793 | | Yes | Reference | Reference | Reference | Reference | | Pretreatment level of CA-125 |  |  |  |  | |  | 9.990522e-06 | 9.990522e-06 | 8.634015e-06 | 3.541717e-05 | | Treatment approach |  |  |  |  | | PCS | Reference | Reference | Reference | Reference | | NACT-ICS | 0.7290635 | 0.7290635 | 0.6300717 | 0.9827000 | | Residual disease after debulking |  |  |  |  | | Macroscopic free | -1.557798 | -1.557798 | -1.346281 | -1.123398 | | ≤1 cm | -0.7263164 | -0.7263164 | -0.6276976 | -0.4524202 | | >1 cm | Reference | Reference | Reference | Reference | | a The closed testing procedure selected ‘model revision’ as the preferred method for updating the postoperative model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | | |
|  |
| Afbeelding met tekst, lijn, diagram, schermopname  Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, Perceel  Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, schermopname, diagram  Automatisch gegenereerde beschrijvingAfbeelding met tekst, lijn, diagram, schermopname  Automatisch gegenereerde beschrijving |

**RESULTS FOR 2ND IMPUTATED DATASET OF THE AUSTRALIAN VALIDATION COHORT (N = 1334)**

EXTERNAL VALIDATION METHOD SELECTED WAS MODEL REVISION

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  | | --- | --- | --- | --- | --- | | **Supplementary table 1.** Model performance of the original model (Postoperative model) and the updated models for the Australian cohort (N = 981) . | | | | | |  | **Original**  **model** | **Recalibration-in-the-large a** | **Recalibration** | **Model revision** | | ***Model performance*** |  |  |  |  | | Calibration interceptc | 0.1875 | 0 | 0 | 0 | | Calibration slopec | 0.8500 | 0. 8500 | 1 | 1 | | *c*-statistic | 0.684 | 0.684 | 0.684 | 0.705 | | Brier score | 0.212 | 0.208 | 0.208 | 0.203 | |  |  |  |  |  | | ***Coefficients*** |  |  |  |  | | Intercept | -1.7507769 | -1.4382701 | -1.3006579 | -0.8708819 | | Age at diagnosis |  |  |  |  | |  | 0.004381937 | 0.004381937 | 0.003724737 | 0.003440634 | | FIGO stage |  |  |  |  | | Stage IIB-IIC | Reference | Reference | Reference | Reference | | Stage IIIA-IIIB | 1.0348905 | 1.0348905 | 0.8796782 | -0.4649788 | | Stage IIIC | 1.1203735 | 1.1203735 | 0.9523405 | 0.3590781 | | Stage IV | 1.4854454 | 1.4854454 | 1.2626591 | 0.8379011 | | Histologic subtype |  |  |  |  | | Serous | Reference | Reference | Reference | Reference | | Mucinous | 1.1962919 | 1.1962919 | 1.0168727 | 0.4833724 | | Endometrioid | 0.02379306 | 0.02379306 | 0.02022459 | -0.32361810 | | Clear cell | 1.000811 | 1.000811 | 0.850710 | 1.467544 | | Adenocarcinoma NOS | -0.06078587 | -0.06078587 | -0.05166924 | -0.46198153 | | Other | 1.0056858 | 1.0056858 | 0.8548536 | 0.5754187 | | Presence of ascites |  |  |  |  | | No | -0.1703497 | -0.1703497 | -0.1448007 | -0.2521676 | | Yes | Reference | Reference | Reference | Reference | | Pretreatment level of CA-125 |  |  |  |  | |  | 9.990522e-06 | 9.990522e-06 | 8.492149e-06 | 2.737180e-05 | | Treatment approach |  |  |  |  | | PCS | Reference | Reference | Reference | Reference | | NACT-ICS | 0.7290635 | 0.7290635 | 0.6197190 | 0.9503971 | | Residual disease after debulking |  |  |  |  | | Macroscopic free | -1.557798 | -1.557798 | -1.324161 | -1.158045 | | ≤1 cm | -0.7263164 | -0.7263164 | -0.6173839 | -0.4503497 | | >1 cm | Reference | Reference | Reference | Reference | | a The closed testing procedure selected ‘model revision’ as the preferred method for updating the postoperative model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | | |

**RESULTS FOR 3RD IMPUTATED DATASET OF THE AUSTRALIAN VALIDATION COHORT (N = 1334)**



EXTERNAL VALIDATION METHOD SELECTED WAS MODEL REVISION



|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  | | --- | --- | --- | --- | --- | | **Supplementary table 1.** Model performance of the original model (Postoperative model) and the updated models for the Australian cohort (N = 1334) . | | | | | |  | **Original**  **model** | **Recalibration-in-the-large a** | **Recalibration** | **Model revision** | | ***Model performance*** |  |  |  |  | | Calibration interceptc | 0.1925 | 0 | 0 | 0 | | Calibration slopec | 0.8510 | 0.8510 | 1 | 1 | | *c*-statistic | 0.686 | 0.686 | 0.686 | 0.701 | | Brier score | 0.212 | 0.208 | 0.208 | 0.203 | |  |  |  |  |  | | ***Coefficients*** |  |  |  |  | | Intercept | -1.7507769 | -1.4330372 | -1.2973188 | -0.9160029 | | Age at diagnosis |  |  |  |  | |  | 0.004381937 | 0.004381937 | 0.003729156 | 0.003818667 | | FIGO stage |  |  |  |  | | Stage IIB-IIC | Reference | Reference | Reference | Reference | | Stage IIIA-IIIB | 1.0348905 | 1.0348905 | 0.8807219 | -0.3838130 | | Stage IIIC | 1.1203735 | 1.1203735 | 0.9534704 | 0.4222857 | | Stage IV | 1.4854454 | 1.4854454 | 1.2641572 | 0.9336473 | | Histologic subtype |  |  |  |  | | Serous | Reference | Reference | Reference | Reference | | Mucinous | 1.1962919 | 1.1962919 | 1.0180792 | 0.3323398 | | Endometrioid | 0.02379306 | 0.02379306 | 0.02024858 | -0.29089250 | | Clear cell | 1.0008111 | 1.0008111 | 0.8517193 | 1.4651485 | | Adenocarcinoma NOS | -0.06078587 | -0.06078587 | -0.05173055 | -0.46921122 | | Other | 1.0056858 | 1.0056858 | 0.8558679 | 0.5338634 | | Presence of ascites |  |  |  |  | | No | -0.1703497 | -0.1703497 | -0.1449725 | -0.2890932 | | Yes | Reference | Reference | Reference | Reference | | Pretreatment level of CA-125 |  |  |  |  | |  | 9.990522e-06 | 9.990522e-06 | 8.502225e-06 | 1.359744e-05 | | Treatment approach |  |  |  |  | | PCS | Reference | Reference | Reference | Reference | | NACT-ICS | 0.7290635 | 0.7290635 | 0.6204542 | 0.9634150 | | Residual disease after debulking |  |  |  |  | | Macroscopic free | -1.557798 | -1.557798 | -1.325732 | -1.156875 | | ≤1 cm | -0.7263164 | -0.7263164 | -0.6181164 | -0.4527512 | | >1 cm | Reference | Reference | Reference | Reference | | a The closed testing procedure selected ‘model revision’ as the preferred method for updating the postoperative model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | | |

**RESULTS OF THE COMPLETE CASE ANALYSIS AUSTRALIAN VALIDATION COHORT (N = 709)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3.** Model performance of the original model (*BRCA* model) and the updated models for the Australian cohort (n = 709). | | | | |
|  | **Originalmodel** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | 0.9117 | 0 | 0 | 0 |
| Calibration slope | 0.9749 | 0.9749 | 1 | 1 |
| *c*-statistic | 0.717 | 0.717 | 0.717 | 0.727 |
| Brier score | 0.231 | 0.200 | 0.200 | 0.197 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -2.0591549 | -1.1117540 | -1.0957839 | -0.4644009 |
| Age at diagnosis |  |  |  |  |
|  | -0.008876547 | -0.008876547 | -0.008653989 | -0.006055101 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.33912164 | 1.33912164 | 1.30554635 | -0.02823605 |
| Stage IIIC | 1.5449104 | 1.5449104 | 1.5061755 | 0.7389049 |
| Stage IV | 1.7119788 | 1.7119788 | 1.6690550 | 0.9857307 |
| *BRCA* status |  |  |  |  |
| *BRCA-negative* | Reference | Reference | Reference | Reference |
| *BRCA1* mutation | -0.6162172 | -0.6162172 | -0.6007670 | -0.6794262 |
| *BRCA2* mutation | -1.6725800 | -1.6725800 | -1.6306441 | -0.9190546 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.572044 | 1.572044 | 1.532629 | 1.232094 |
| Endometrioid | -0.2965935 | -0.2965935 | -0.2891571 | -0.3085555 |
| Clear cell | 0.7662715 | 0.7662715 | 0.7470591 | 1.1796124 |
| Adenocarcinoma NOS | 0.01501892 | 0.01501892 | 0.01464235 | -0.39938501 |
| Other | 0.7582711 | 0.7582711 | 0.7392593 | 0.7567724 |
| Presence of ascites |  |  |  |  |
| No | -0.1338588 | -0.1338588 | -0.1305026 | -0.3292264 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  | 1.828824e-05 | 1.828824e-05 | 1.782970e-05 | 1.657175e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.9895219 | 0.9895219 | 0.9647120 | 1.4587970 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.240264 | -1.240264 | -1.209167 | -1.226220 |
| ≤1 cm | -0.4503319 | -0.4503319 | -0.4390409 | -0.5838670 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected ‘recalibration-in-the-large’ as the preferred method for updating the BRCA model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |





**RESULTS FOR 1ST IMPUTATED DATASET OF THE AUSTRALIAN VALIDATION COHORT (N = 958)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3.** Model performance of the original model (*BRCA* model) and the updated models for the Australian cohort (n = 958). | | | | |
|  | **Original BRCA**  **model** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | 0.6779 | 0 | 0 | 0 |
| Calibration slope | 0.8695 | 0.8695 | 1 | 1 |
| *c*-statistic | 0.700 | 0.700 | 0.700 | 0.706 |
| Brier score | 0.222 | 0.199 | 0.199 | 0.198 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -2.0591549 | -1.1941105 | -1.1125368 | -0.5113698 |
| Age at diagnosis |  |  |  |  |
|  | -0.008876547 | -0.008876547 | -0.007718007 | -0.004517699 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.3391216 | 1.3391216 | 1.1643436 | -0.4579562 |
| Stage IIIC | 1.5449104 | 1.5449104 | 1.3432735 | 0.5121913 |
| Stage IV | 1.711979 | 1.711979 | 1.488537 | 0.883046 |
| *BRCA* status |  |  |  |  |
| *BRCA-negative* | Reference | Reference | Reference | Reference |
| *BRCA1* mutation | -0.6162172 | -0.6162172 | -0.5357904 | -0.6536941 |
| *BRCA2* mutation | -1.672580 | -1.672580 | -1.454280 | -1.013298 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.572044 | 1.572044 | 1.366866 | -4.280278 |
| Endometrioid | -0.2965935 | -0.2965935 | -0.2578830 | -0.5236191 |
| Clear cell | 0.7662715 | 0.7662715 | 0.6662601 | 1.2027166 |
| Adenocarcinoma NOS | 0.01501892 | 0.01501892 | 0.01305869 | -0.25539782 |
| Other | 0.7582711 | 0.7582711 | 0.6593039 | 0.6310432 |
| Presence of ascites |  |  |  |  |
| No | -0.1338588 | -0.1338588 | -0.1163880 | -0.4460152 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  |  |  |  |  |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.9895219 | 0.9895219 | 0.8603726 | 1.1824363 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.2402636 | -1.2402636 | -1.0783882 | -0.9225449 |
| ≤1 cm | -0.4503319 | -0.4503319 | -0.3915560 | -0.3985658 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected “recalibration-in-the-large” as the preferred method for updating the BRCA model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |

**RESULTS FOR 2ND IMPUTATED DATASET OF THE AUSTRALIAN VALIDATION COHORT (N = 958)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3.** Model performance of the original model (*BRCA* model) and the updated models for the Dutch cohort (n = 793). | | | | |
|  | ***BRCA* model** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | 0.6732 | 0 | 0 | 0 |
| Calibration slope | 0.8706 | 0.8706 | 1 | 1 |
| *c*-statistic | 0.705 | 0.705 | 0.705 | 0.710 |
| Brier score | 0.221 | 0.198 | 0.198 | 0.197 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -2.0591549 | -1.2011753 | -1.1194546 | -0.4413379 |
| Age at diagnosis |  |  |  |  |
|  | -0.008876547 | -0.008876547 | -0.007727938 | -0.004628110 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.3391216 | 1.3391216 | 1.1658417 | -0.4632041 |
| Stage IIIC | 1.5449104 | 1.5449104 | 1.3450018 | 0.5050073 |
| Stage IV | 1.7119788 | 1.7119788 | 1.4904518 | 0.8690586 |
| *BRCA* status |  |  |  |  |
| *BRCA-negative* | Reference | Reference | Reference | Reference |
| *BRCA1* mutation | -0.6162172 | -0.6162172 | -0.5364798 | -0.6428220 |
| *BRCA2* mutation | -1.6725800 | -1.6725800 | -1.4561511 | -0.9875161 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.572044 | 1.572044 | 1.368625 | -4.195217 |
| Endometrioid | -0.2965935 | -0.2965935 | -0.2582148 | -0.5165245 |
| Clear cell | 0.7662715 | 0.7662715 | 0.6671173 | 1.2149974 |
| Adenocarcinoma NOS | 0.01501892 | 0.01501892 | 0.01307550 | -0.30053468 |
| Other | 0.7582711 | 0.7582711 | 0.6601522 | 0.6280667 |
| Presence of ascites |  |  |  |  |
| No | -0.1338588 | -0.1338588 | -0.1165377 | -0.3370409 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  | 1.828824e-05 | 1.828824e-05 | 1.592177e-05 | 6.867290e-06 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.9895219 | 0.9895219 | 0.8614795 | 1.1533286 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.240264 | -1.240264 | -1.079776 | -1.067053 |
| ≤1 cm | -0.4503319 | -0.4503319 | -0.3920598 | -0.4440554 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected “recalibration-in-the-large” as the preferred method for updating the BRCA model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |

**RESULTS FOR 3RD IMPUTATED DATASET OF THE AUSTRALIAN VALIDATION COHORT (N = 958)**

EXTERNAL VALIDATION METHOD SELECTED WAS RECALIBRATION-IN-THE-LARGE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 3.** Model performance of the original model (*BRCA* model) and the updated models for the Dutch cohort (n = 793). | | | | |
|  | ***BRCA* model** | **Recalibration-in-the-large** | **Recalibration** | **Model revision** |
| ***Model performance*** |  |  |  |  |
| Calibration intercept | 0.6840 | 0 | 0 | 0 |
| Calibration slope | 0.8734 | 0.8734 | 1 | 1 |
| *c*-statistic | 0.703 | 0.703 | 0.703 | 0.709 |
| Brier score | 0.221 | 0.198 | 0.198 | 0.198 |
|  |  |  |  |  |
| ***Coefficients*** |  |  |  |  |
| Intercept | -2.0591549 | -1.1937639 | -1.1145877 | -0.5030689 |
| Age at diagnosis |  |  |  |  |
|  | -0.008876547 | -0.008876547 | -0.007753128 | -0.005399266 |
| FIGO stage |  |  |  |  |
| Stage IIB-IIC | Reference | Reference | Reference | Reference |
| Stage IIIA-IIIB | 1.3391216 | 1.3391216 | 1.1696419 | -0.4603667 |
| Stage IIIC | 1.5449104 | 1.5449104 | 1.3493860 | 0.5230125 |
| Stage IV | 1.7119788 | 1.7119788 | 1.4953102 | 0.8844453 |
| *BRCA* status |  |  |  |  |
| *BRCA-negative* | Reference | Reference | Reference | Reference |
| *BRCA1* mutation | -0.6162172 | -0.6162172 | -0.5382285 | -0.6698873 |
| *BRCA2* mutation | -1.672580 | -1.672580 | -1.460898 | -0.998497 |
| Histologic subtype |  |  |  |  |
| Serous | Reference | Reference | Reference | Reference |
| Mucinous | 1.572044 | 1.572044 | 1.373086 | -4.155978 |
| Endometrioid | -0.2965935 | -0.2965935 | -0.2590565 | -0.5249281 |
| Clear cell | 0.7662715 | 0.7662715 | 0.6692919 | 1.1665754 |
| Adenocarcinoma NOS | 0.01501892 | 0.01501892 | 0.01311812 | -0.31698685 |
| Other | 0.7582711 | 0.7582711 | 0.6623041 | 0.6264980 |
| Presence of ascites |  |  |  |  |
| No | -0.1338588 | -0.1338588 | -0.1169176 | -0.2273191 |
| Yes | Reference | Reference | Reference | Reference |
| Pretreatment CA-125 |  |  |  |  |
|  | 1.828824e-05 | 1.828824e-05 | 1.597367e-05 | 2.184864e-05 |
| Treatment approach |  |  |  |  |
| PCS | Reference | Reference | Reference | Reference |
| NACT-ICS | 0.9895219 | 0.9895219 | 0.8642877 | 1.1020178 |
| Residual disease after debulking |  |  |  |  |
| Macroscopic free | -1.240264 | -1.240264 | -1.083295 | -1.016992 |
| ≤1 cm | -0.4503319 | -0.4503319 | -0.3933378 | -0.3667385 |
| >1 cm | Reference | Reference | Reference | Reference |
| a The closed testing procedure selected “recalibration-in-the-large” as the preferred method for updating the BRCA model.  c The calibration intercept and slope represent the estimates of miscalibration of the models. Thus, it represents the correction factor needed to improve calibration of the model. | | | | |